{"id":"https://openalex.org/W1930126355","doi":null,"title":"Optimizing outcomes for GLP-1 agonists.","display_name":"Optimizing outcomes for GLP-1 agonists.","publication_year":2011,"publication_date":"2011-02-01","ids":{"openalex":"https://openalex.org/W1930126355","mag":"1930126355","pmid":"https://pubmed.ncbi.nlm.nih.gov/21389295"},"language":"en","primary_location":{"id":"pmid:21389295","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21389295","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of the American Osteopathic Association","raw_type":"Case Reports"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103182242","display_name":"Jeffrey S. Freeman","orcid":"https://orcid.org/0009-0009-7153-4302","observed_orcids":["https://orcid.org/0009-0009-7153-4302"]},"institutions":[{"id":"https://openalex.org/I106460735","display_name":"Philadelphia College of Osteopathic Medicine","ror":"https://ror.org/00m9c2804","country_code":"US","type":"education","lineage":["https://openalex.org/I106460735"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jeffrey S Freeman","raw_affiliation_strings":["Division of Endocrinology and Metabolism, Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131-1633, USA. jeffreyfreemando@aol.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Endocrinology and Metabolism, Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131-1633, USA. jeffreyfreemando@aol.com","institution_ids":["https://openalex.org/I106460735"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5103182242"],"corresponding_institution_ids":["https://openalex.org/I106460735"],"apc_list":null,"apc_paid":null,"fwci":1.6433,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.82237215,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"111","issue":"2 Suppl 1","first_page":"eS15","last_page":"20"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.921999990940094},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9879999756813049},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8989999890327454},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.6869999766349792},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9160000085830688},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.4779999852180481},{"id":"https://openalex.org/keywords/dosing-and-administration","display_name":"dosing and administration","score":0.5099999904632568},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.6539999842643738},{"id":"https://openalex.org/keywords/patient-expectations","display_name":"patient expectations","score":0.7680000066757202},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.5059999823570251}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9572856426239014},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7681130766868591},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.7269046306610107},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6952394247055054},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.5552988648414612},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5280381441116333},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5196834206581116},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5166543126106262},{"id":"https://openalex.org/C2778854520","wikidata":"https://www.wikidata.org/wiki/Q418776","display_name":"Sulfonylurea","level":3,"score":0.48229506611824036},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.48209884762763977},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.47917309403419495},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.46662768721580505},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.4103041887283325},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3559211492538452},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.22259780764579773},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.18365395069122314},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09970203042030334}],"mesh":[{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":false},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"pmid:21389295","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21389295","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of the American Osteopathic Association","raw_type":"Case Reports"},{"id":"pmh:oai:digitalcommons.pcom.edu:scholarly_papers-1267","doi":null,"is_oa":false,"landing_page_url":"https://digitalcommons.pcom.edu/scholarly_papers/151","pdf_url":null,"source":{"id":"https://openalex.org/S4377196547","display_name":"Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I106460735","host_organization_name":"Philadelphia College of Osteopathic Medicine","host_organization_lineage":["https://openalex.org/I106460735"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"PCOM Scholarly Works","raw_type":"text"},{"id":"mag:1930126355","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21389295","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W100598291","https://openalex.org/W1958461722","https://openalex.org/W1970638723","https://openalex.org/W1980855817","https://openalex.org/W1984410261","https://openalex.org/W1985138942","https://openalex.org/W2001097346","https://openalex.org/W2024569808","https://openalex.org/W2039665646","https://openalex.org/W2058468402","https://openalex.org/W2058922633","https://openalex.org/W2059764669","https://openalex.org/W2062883844","https://openalex.org/W2070710390","https://openalex.org/W2088271055","https://openalex.org/W2098459806","https://openalex.org/W2103525547","https://openalex.org/W2107680428","https://openalex.org/W2108646121","https://openalex.org/W2113182836","https://openalex.org/W2118762421","https://openalex.org/W2122530526","https://openalex.org/W2140536043","https://openalex.org/W2144611099","https://openalex.org/W2146901298","https://openalex.org/W2156108549","https://openalex.org/W2162449758","https://openalex.org/W2170606300","https://openalex.org/W2198678228"],"related_works":["https://openalex.org/W2084504997","https://openalex.org/W2119355349","https://openalex.org/W952614140","https://openalex.org/W2109093140","https://openalex.org/W3007992093","https://openalex.org/W2262074101","https://openalex.org/W1984805996","https://openalex.org/W1863540633","https://openalex.org/W2103684966","https://openalex.org/W1788528477"],"abstract_inverted_index":{"The":[0,191],"management":[1],"of":[2,36,44,59,85,92,114,126,147,170,193,209,221,237],"type":[3],"2":[4],"diabetes":[5],"mellitus":[6],"and,":[7],"in":[8,52,81,90,144,225],"particular,":[9],"blood":[10,54],"glucose":[11,55,115],"levels":[12],"can":[13,136],"be":[14,137,158,165,183,199],"complex":[15],"and":[16,20,40,64,88,117,163,215,218],"challenging":[17],"for":[18,104],"physicians":[19],"patients.":[21],"Many":[22],"patients":[23,105,119],"are":[24,79,152],"frustrated":[25],"with":[26,61,68,98,160,167,178,233],"the":[27,82,86,112,123,145,226],"agents":[28],"currently":[29],"available":[30],"because":[31],"they":[32],"have":[33,132],"associated":[34,159,166],"limitations":[35],"weight":[37,62,69],"gain,":[38,63],"hypoglycemia,":[39],"tolerability":[41],"issues.":[42],"Advantages":[43],"glucagon-like":[45],"peptide-1":[46],"(GLP-1)":[47],"agonists":[48,141,151],"include":[49],"their":[50,57,65],"efficacy":[51],"lowering":[53],"levels,":[56],"lack":[58],"association":[60,67],"indirect":[66],"loss.":[70],"Patients":[71,128],"likely":[72],"to":[73,157,186,198,229],"benefit":[74,94],"from":[75,95],"GLP-1":[76,140,150,179,203],"agonist":[77,204],"therapy":[78,177,222],"those":[80,89],"early":[83],"stages":[84],"disease":[87],"need":[91,197],"sufficient":[93],"an":[96],"agent":[97],"good":[99],"efficacy.":[100],"Setting":[101],"appropriate":[102],"expectations":[103],"is":[106,122,205,223],"important,":[107],"as":[108,110],"well":[109],"explaining":[111],"significance":[113],"control":[116],"reminding":[118],"that":[120,139],"this":[121,234],"main":[124],"goal":[125],"therapy.":[127],"(and":[129],"physicians)":[130],"who":[131],"concerns":[133],"about":[134],"hypoglycemia":[135],"reassured":[138],"work":[142],"only":[143],"presence":[146],"hyperglycemia.":[148],"Longer-acting":[149],"dosed":[153],"less":[154,161],"frequently,":[155],"appear":[156],"nausea,":[162],"may":[164,196],"better":[168],"rates":[169,232],"adherence":[171],"than":[172],"shorter-acting":[173],"agents.":[174,238],"When":[175],"initiating":[176],"agonists,":[180],"doses":[181],"should":[182],"gradually":[184],"escalated":[185],"minimize":[187],"gastrointestinal":[188],"adverse":[189,211],"effects.":[190],"dose":[192],"a":[194,202],"sulfonylurea":[195],"lowered":[200],"if":[201],"added.":[206],"A":[207],"review":[208],"possible":[210],"effects,":[212],"contraindications,":[213],"dosing":[214],"administration":[216],"techniques,":[217],"expected":[219],"benefits":[220],"provided":[224],"present":[227],"article":[228],"optimize":[230],"success":[231],"new":[235],"class":[236]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}